Medline (NASDAQ:MDLN) Price Target Cut to $46.00 by Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan cut Medline’s price target from $53 to $46 while maintaining an “overweight” rating, implying approximately 31% upside from the stock’s $35.04 price.
• Medline reported quarterly EPS of $0.50, beating the $0.32 consensus estimate, on $7.68 billion in revenue. Analysts collectively maintain a “Moderate Buy” rating with an average target of $47.42.
• Several brokerages have also lowered their targets, while insider selling has been significant: insiders sold nearly $104.7 million of stock over the past 90 days, despite one reported insider purchase.

Medline (NASDAQ:MDLN - Get Free Report) had its price objective lowered by research analysts at JPMorgan Chase & Co. from $53.00 to $46.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 31.29% from the stock's current price.

Several other brokerages have also issued reports on MDLN. Barclays cut their target price on shares of Medline from $50.00 to $45.00 and set an "overweight" rating on the stock in a research note on Monday, June 1st. Weiss Ratings upgraded shares of Medline from a "sell (d)" rating to a "sell (d+)" rating in a report on Thursday, August 6th. Sanford C. Bernstein cut their price objective on shares of Medline from $56.00 to $54.00 and set an "outperform" rating on the stock in a research report on Thursday, May 7th. BTIG Research restated a "buy" rating and issued a $55.00 target price on shares of Medline in a research note on Friday, July 31st. Finally, Robert W. Baird set a $42.00 price target on Medline in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $47.42.

Medline Trading Down 0.0%

NASDAQ MDLN traded down $0.00 during trading hours on Wednesday, hitting $35.04. 1,159,933 shares of the company's stock were exchanged, compared to its average volume of 7,361,199. The firm has a market cap of $46.03 billion and a price-to-earnings ratio of 109.72. The stock has a 50-day simple moving average of $38.21 and a 200 day simple moving average of $41.57. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. Medline has a 1-year low of $32.81 and a 1-year high of $50.88.

Medline (NASDAQ:MDLN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion during the quarter. On average, equities analysts forecast that Medline will post 1.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Douglas P. Golwas sold 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total value of $3,677,000.00. Following the transaction, the insider owned 23,899 shares in the company, valued at $878,766.23. This trade represents a 80.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jessi L. Corcoran purchased 5,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was bought at an average cost of $34.15 per share, with a total value of $170,750.00. Following the completion of the transaction, the insider directly owned 5,000 shares in the company, valued at $170,750. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders sold 2,938,896 shares of company stock valued at $104,656,454. Corporate insiders own 0.81% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in Medline in the 2nd quarter worth about $40,430,000. E. Ohman J or Asset Management AB bought a new position in shares of Medline during the 2nd quarter worth approximately $508,000. GAMMA Investing LLC boosted its stake in shares of Medline by 68.3% in the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company's stock worth $25,000 after buying an additional 254 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Medline by 1,073.3% in the 1st quarter. Parallel Advisors LLC now owns 5,280 shares of the company's stock worth $235,000 after buying an additional 4,830 shares during the last quarter. Finally, CTC Alternative Strategies Ltd. bought a new position in shares of Medline in the first quarter valued at approximately $1,048,000.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: TD Cowen maintained a Buy rating while lowering its price target from $53 to $45. The target still implies meaningful upside and reflects confidence in Medline’s cash flow and longer-term growth outlook. TD Cowen price target report
• Positive Sentiment: Tigress Financial also retained a Buy rating despite cutting its target from $62 to $55, indicating that the firm views the recent weakness as excessive and expects substantial potential appreciation. Tigress Financial analyst action
• Positive Sentiment: Medline recently reported quarterly EPS of $0.50, well above the $0.32 consensus estimate, on approximately $7.7 billion in revenue. The earnings beat may help offset concerns about valuation and near-term analyst downgrades.
• Neutral Sentiment: Recent institutional activity included new positions and increased holdings by several investment firms. Reported short interest was zero, although the data appears incomplete and offers limited insight into trading pressure.
• Negative Sentiment: Wells Fargo lowered its price target from $45 to $34 and assigned an Equal Weight rating. Its target is near or slightly below recent trading levels, signaling limited near-term upside. Wells Fargo price target report
• Negative Sentiment: Major shareholder Private Ltd Gic sold 590,284 shares for roughly $21 million, reducing its stake by 2.36%. Including sales disclosed for August 5 and 6, the investor has recently sold nearly 2.84 million shares, which may weigh on sentiment. Medline shareholder sale
• Negative Sentiment: Kaplan Fox is investigating potential securities-law violations involving Medline. The announcement does not establish wrongdoing, but it adds legal and reputational uncertainty for investors. Kaplan Fox investigation

About Medline

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source